LLRAPC Standards for Prescribing across the NHS-Private Interface(586 KB) - Guidelines
Date added: 9th May 2024
Drug Name | Classification | Clinical Indication | Comments |
---|---|---|---|
DAPSONE (UPDATED) | Orange | Dermatology |
See shared care agreement for details. |
Etrasimod (Velsipity®) (NEW) | Red | Severely active ulcerative colitis |
In line with NICE TA956 |
NEFOPAM (NEW) | Red | For post-operative analgesia for patients undergoing THR / TKR |
ONLY for patients who are intolerant of NSAIDs, tramadol and/or opioids. 5 – 7 days treatment only. |
Recent documents from LLR APC and TAS
Date added: 9th May 2024
Date added: 9th May 2024
Date added: 9th May 2024
Date added: 1st May 2024
Date added: 1st May 2024
Date added: 25th Apr 2024
Version 2.3 Uploaded April 2024
Date added: 2nd May 2019
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more